Source: Pharmacy Times articles
Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.
Read More
by MM360 Staff | Jun 3, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.
Read More